Substituted heterocyclo-norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and medicaments comprising them

US6737423B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Uwe Heinelt · Wiesbaden, DE
• Hans-Jochen Lang · Hofheim, DE
• Klaus Wirth · Frankfurt am Main, DE
• Hans-Willi Jansen · Niedernhausen, DE

Key dates

• Filing date: Dec 18, 2001
• Grant date: May 18, 2004
• Expiry date: Jan 19, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D333/44
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Substituted heterocyclo-norbornylaminoderivatives having: a) an exo-configuration nitrogen and an endo-fused five-membered ring or six-membered ring of the formula (I) or b) an exo-configuration nitrogen and an exo-fused five-membered ring or six-membered ring of the formula (I a), wherein Rn, Het, A, B and T have the meanings given in the claims. These compounds have a variety of uses. They can be used as antihypertensives, for the reduction or prevention of is chemically induced damage, as pharmaceuticals for surgical interventions, for the treatment of ischemia of the nervous system, including stroke and cerebral edema, for the treatment of ischemia due to shock and disturbed respiratory drive, for the treatment of snoring, as a laxative, as an agent against ectoparasites, for the prevention of gallstone formation, as an antiatherosclerotic, as an agent against diabetic late complications, cancers, fibrotic disorders, endothelial dysfunction, organ hypertrophy, and organ hyperplasia.The compounds of the invention are inhibitors of the cellular sodium-proton antiporter. Additonally, the compounds of the invention influence the serum lipoproteins and can therefore be used for the …